May 2026: Wegovy HD Goes Nationwide, Foundayo Hits Telehealth, and FDA Moves to Permanently Ban Compounded GLP-1s
April delivered the biggest GLP-1 catalyst in years — Wegovy HD launched nationwide, Lilly's Foundayo pill hit pharmacies and telehealth, Medicare Zepbound coverage went live, and the FDA proposed a permanent ban on mass compounding of semaglutide and tirzepatide. Here's what changed and what it means for your provider choice.
April 2026 turned out to be the most consequential month for the GLP-1 market since Wegovy was first approved. Three major launches landed within ten days of each other — Foundayo, Wegovy HD, and Medicare Zepbound coverage — and the FDA used the same window to propose a permanent end to mass compounding of GLP-1s. Here’s everything we updated across our 50+ provider profiles for May, plus what each change means for your choice of provider.
The Biggest Headlines
Foundayo (Orforglipron) — The First No-Restriction GLP-1 Pill
The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the second oral GLP-1 on the market and the only one that can be taken any time of day with no food or water restrictions. Lilly began shipping through LillyDirect, Amazon Pharmacy, and Prescryptive on April 6, and LifeMD became the first major telehealth platform to add Foundayo just four days later.
Self-pay pricing is aggressive:
- 0.8 mg starter: $149/month
- 2.5 mg: $199/month
- 5.5–9 mg: $299/month
- 14.5–17.2 mg: $299/month (continuous refills) or $349/month (gaps over 45 days)
Commercially insured patients with the Foundayo Savings Card can pay as little as $25/month. Medicare coverage is expected to begin July 1, 2026 at a $50/month copay through the GLP-1 Bridge program.
Trial efficacy: ~12.4% average weight loss at 72 weeks. That’s meaningfully less than injectables (Zepbound ~21%, Wegovy HD ~21%), but Foundayo’s flexibility removes a real adherence barrier. Patients who failed at strict morning-only oral Wegovy dosing now have a much friendlier alternative.
We’ve updated LillyDirect and LifeMD with full Foundayo pricing tables. Other LillyDirect telehealth partners (Ro, Teladoc, Form Health, knownwell) are expected to add Foundayo throughout May.
Wegovy HD 7.2mg — Nationwide on April 7
Just six days after Foundayo’s launch, Novo Nordisk’s Wegovy HD (semaglutide 7.2mg injection) became available nationwide on April 7, 2026 through 70,000+ U.S. pharmacies, NovoCare Pharmacy, and select telehealth providers. This is the highest-dose Wegovy injection ever approved.
- Self-pay: $399/month
- Clinical: ~21% average weight loss at 72 weeks (STEP UP trial), now matching Zepbound’s efficacy ceiling
- Use case: Patients who plateaued on Wegovy 2.4mg but want to stay on semaglutide rather than switching to tirzepatide
Wegovy HD is now available across all 8 of Novo Nordisk’s telehealth partners (Ro, LifeMD, GoodRx Care, WeightWatchers Clinic, knownwell, Hims, eMed, Costco/Sesame) plus direct via NovoCare.
Wegovy Injection Intro Pricing Extended Through June 30
In a small but consumer-friendly move, Novo extended the Wegovy injection $199/month intro offer (first 2 fills of 0.25mg or 0.5mg) from its original March 31 sunset to June 30, 2026. After the intro period, prices step up to $349/month for all standard doses (0.25–2.4mg) or $399/month for Wegovy HD 7.2mg.
We’ve updated Ro, GoodRx Care, LifeMD, PlushCare, and NovoCare to reflect the extension.
Medicare Zepbound Coverage Went Live April 1
Zepbound KwikPen Medicare Part D coverage at the $50/month copay went live on April 1, 2026 as scheduled. Eligible Medicare beneficiaries can now access tirzepatide through any Part D plan that has added Zepbound to formulary, with prior authorization required and obesity-with-comorbidities as the primary use case (BMI ≥30, or ≥27 with conditions like CVD, hypertension, dyslipidemia, or sleep apnea).
This is a meaningful change — for the 67 million Americans on Medicare, branded GLP-1 just became as affordable as compounded.
CMS BALANCE Model Update — Bridge Extended Through 2027
On April 21, 2026, CMS announced a notable course correction: the BALANCE Model will not be implemented in Medicare Part D in 2027 as originally planned. Instead, the Medicare GLP-1 Bridge program will be extended through 2027.
What this means in practice:
- Medicare Bridge (covering Wegovy, Ozempic, Mounjaro, Rybelsus, Zepbound KwikPen, and Foundayo at $50/month) launches July 1, 2026 and now runs through December 31, 2027 instead of sunsetting at the end of 2026
- BALANCE Model is still launching for state Medicaid agencies in May 2026 — that piece is moving forward
- Net effect: more continuity for Medicare beneficiaries; no abrupt formulary or program switch at the end of 2026
FDA Moves to Permanently Ban Mass Compounding
This is the headline that may matter most for the long-term shape of the market. In late April, the FDA published a proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively shutting down mass compounding of these GLP-1s by 503B outsourcing facilities.
- Public comments are open through June 29, 2026
- The FDA cited 455+ adverse event reports for compounded semaglutide and 320+ for compounded tirzepatide as of early 2025, many tied to dosing errors from multidose vials
- A loophole may remain for medical spas and certain telehealth companies operating under 503A patient-specific compounding rules — but that’s a narrower path than the current model
Combined with the existing FDA warning letters (80+ since September 2025) and the rapid migration of major players away from compounding (Hims to Novo branded, Ro to LillyDirect/Foundayo), the runway for mass-marketed compounded GLP-1s is shrinking fast.
Our take: Compounded providers still offer real value for cash-pay patients today, but every patient on compounded semaglutide or tirzepatide should have a branded backup plan. Between Medicare coverage at $50/month, Foundayo at $149/month self-pay, and Wegovy injection intro at $199/month, the economic case for compounded is thinner than it was even six months ago.
Provider Landscape Changes
Hims — SEC Investigation Still Open
Hims & Hers is in a strange middle state: the Novo Nordisk lawsuit is settled (they’re now an authorized seller of branded Wegovy and Ozempic), but the SEC investigation into the company’s prior GLP-1 disclosures remains open. Mid-April reports also flagged a July advisory review on broader peptide access that could open a new wellness/metabolic product category for Hims to repurpose its compounding infrastructure. We’re keeping Hims out of our top rankings until the SEC investigation resolves.
Retatrutide — Phase 3 Wins, But a New Safety Signal
Lilly’s triple-agonist retatrutide posted strong TRIUMPH-4 Phase 3 results: 28.7% average weight loss at 68 weeks (~71 lbs) plus a 75.8% reduction in WOMAC knee osteoarthritis pain scores. But Lilly also disclosed a new safety signal — dysesthesia (abnormal sensations of touch) at 8.8% on the 9 mg dose and 20.9% on the 12 mg dose, vs. 0.7% on placebo. Seven more Phase 3 readouts are expected in 2026. Retatrutide remains on track to be the most effective weight loss medication ever approved (likely 2027–2028), but the dysesthesia rate is something to watch.
Compounder Migration
The biggest behavioral shift this quarter is the migration of branded telehealth platforms away from compounded GLP-1s:
- Hims → settled with Novo, now selling branded Wegovy/Ozempic, ended compounded semaglutide promotion
- Ro → struck a deal with Lilly to prescribe Foundayo, expanded Wegovy HD access
- LifeMD → first major platform to add Foundayo, full Wegovy HD lineup live
Compounded-only providers — and there are still many in our database — face headwinds from every direction: falling branded prices, expanding Medicare coverage, expired FDA shortage exemptions, and the new proposed permanent ban.
Updated Pricing Snapshot (May 2026)
| Option | Monthly Cost | Status |
|---|---|---|
| Foundayo (orforglipron) | $149–349/mo self-pay; $25 with insurance | Live, broadly available |
| Wegovy pill | $199–299/mo self-pay | Available; intro $149 ended Apr 15 |
| Wegovy injection | $199/mo intro through June 30; $349 standard | Available |
| Wegovy HD 7.2mg | $399/mo | Live nationwide since April 7 |
| Zepbound vials/KwikPen | $299–449/mo | Available |
| Zepbound (Medicare) | $50/mo copay | LIVE since April 1 |
| Foundayo (Medicare) | $50/mo copay (expected) | Starting July 1, 2026 |
| TrumpRx.gov | ~$350/mo | Live |
| Compounded semaglutide | $45–299/mo | Regulatory risk increasing |
Rankings Impact
Our provider rankings reflect the May 2026 reality:
- LifeMD strengthens as the most complete brand-name platform — only telehealth provider with Wegovy, Wegovy HD, Zepbound, and Foundayo
- LillyDirect is now the cleanest manufacturer-direct option, offering both Zepbound and Foundayo with Medicare-friendly pricing
- NovoCare carries Wegovy HD plus the extended $199 injection intro through June 30
- Ro retains a top recommendation for patients wanting both branded and compounded options with strong clinical support
- Hims stays out of our top rankings pending SEC resolution
- Compounded-only providers continue to face increasing regulatory risk; we flag this prominently on every profile
See our full Best GLP-1 Providers rankings, updated for May 2026.
Last updated: May 3, 2026. The GLP-1 market is moving fast — always verify pricing and availability with your provider before starting treatment.